Gonadal steroid-dependent effects on bone turnover and bone mineral density in men
- PMID: 26901812
- PMCID: PMC4767351
- DOI: 10.1172/JCI84137
Gonadal steroid-dependent effects on bone turnover and bone mineral density in men
Abstract
Background: Severe gonadal steroid deficiency induces bone loss in adult men; however, the specific roles of androgen and estrogen deficiency in hypogonadal bone loss are unclear. Additionally, the threshold levels of testosterone and estradiol that initiate bone loss are uncertain.
Methods: One hundred ninety-eight healthy men, ages 20-50, received goserelin acetate, which suppresses endogenous gonadal steroid production, and were randomized to treatment with 0, 1.25, 2.5, 5, or 10 grams of testosterone gel daily for 16 weeks. An additional cohort of 202 men was randomized to receive these treatments plus anastrozole, which suppresses conversion of androgens to estrogens. Thirty-seven men served as controls and received placebos for goserelin and testosterone. Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA), and BMD by quantitative computed tomography (QCT) were assessed in all men. Bone microarchitecture was assessed in 100 men.
Results: As testosterone dosage decreased, the percent change in C-telopeptide increased. These increases were considerably greater when aromatization of testosterone to estradiol was also suppressed, suggesting effects of both testosterone and estradiol deficiency. Decreases in DXA BMD were observed when aromatization was suppressed but were modest in most groups. QCT spine BMD fell substantially in all testosterone-dose groups in which aromatization was also suppressed, and this decline was independent of testosterone dose. Estradiol deficiency disrupted cortical microarchitecture at peripheral sites. Estradiol levels above 10 pg/ml and testosterone levels above 200 ng/dl were generally sufficient to prevent increases in bone resorption and decreases in BMD in men.
Conclusions: Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton.
Trial registration: ClinicalTrials.gov, NCT00114114.
Funding: AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.
Figures





Comment in
-
Battle of the sex steroids in the male skeleton: and the winner is...J Clin Invest. 2016 Mar 1;126(3):829-32. doi: 10.1172/JCI85006. Epub 2016 Feb 22. J Clin Invest. 2016. PMID: 26901810 Free PMC article.
Similar articles
-
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.Osteoporos Int. 2005 Dec;16(12):1487-94. doi: 10.1007/s00198-005-1890-8. Epub 2005 Apr 23. Osteoporos Int. 2005. PMID: 15856361 Clinical Trial.
-
Differential effects of androgens and estrogens on bone turnover in normal men.J Clin Endocrinol Metab. 2003 Jan;88(1):204-10. doi: 10.1210/jc.2002-021036. J Clin Endocrinol Metab. 2003. PMID: 12519853 Clinical Trial.
-
Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.J Bone Miner Res. 1997 Mar;12(3):472-8. doi: 10.1359/jbmr.1997.12.3.472. J Bone Miner Res. 1997. PMID: 9076591 Clinical Trial.
-
Estrogen and bone health in men and women.Steroids. 2015 Jul;99(Pt A):11-5. doi: 10.1016/j.steroids.2014.12.010. Epub 2014 Dec 30. Steroids. 2015. PMID: 25555470 Review.
-
Corticosteroid-induced bone loss in men.J Clin Endocrinol Metab. 1998 Mar;83(3):801-6. doi: 10.1210/jcem.83.3.4621. J Clin Endocrinol Metab. 1998. PMID: 9506731 Review.
Cited by
-
Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.Endocrine. 2019 Sep;65(3):692-706. doi: 10.1007/s12020-019-02008-6. Epub 2019 Jul 19. Endocrine. 2019. PMID: 31325085 Free PMC article. Clinical Trial.
-
Bone mineral density and estimated hip strength in men with anorexia nervosa, atypical anorexia nervosa and avoidant/restrictive food intake disorder.Clin Endocrinol (Oxf). 2019 Jun;90(6):789-797. doi: 10.1111/cen.13960. Epub 2019 Apr 1. Clin Endocrinol (Oxf). 2019. PMID: 30817009 Free PMC article.
-
Diagnosis and therapeutic approach to bone health in patients with hypopituitarism.Rev Endocr Metab Disord. 2024 Jun;25(3):513-539. doi: 10.1007/s11154-024-09878-w. Epub 2024 Apr 3. Rev Endocr Metab Disord. 2024. PMID: 38565758 Review.
-
Bone Remodeling and the Microbiome.Cold Spring Harb Perspect Med. 2018 Apr 2;8(4):a031203. doi: 10.1101/cshperspect.a031203. Cold Spring Harb Perspect Med. 2018. PMID: 28847904 Free PMC article. Review.
-
Effect of Testosterone on Natriuretic Peptide Levels.J Am Coll Cardiol. 2019 Mar 26;73(11):1288-1296. doi: 10.1016/j.jacc.2018.12.062. J Am Coll Cardiol. 2019. PMID: 30898204 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials